Galecto

GLTO

Market cap $43.7M

Two obscure US biotech and medtech names – Galecto Inc (NASDAQ: GLTO) and Movano Inc (NASDAQ: MOVE) – stunned markets today with explosive rallies, each surging roughly 300%. While the gains were triggered by company-specific news, the magnitude of the moves has drawn speculative interest from retail traders and momentum chasers.

Galecto Inc. (NASDAQ:GLTO) stock tripled on Monday, with a session volume of 23.26 million, compared to the average volume of 2.41 million, as per data from Benzinga Pro.

Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results for the quarter ended September 30, 2025.

Galecto Inc. (NASDAQ:GLTO) stock spiked on Tuesday, with a session volume of 61.11 million, compared to the average volume of 984,320, as per data from Benzinga Pro.

Galecto stock (NASDAQ: GLTO) went absolutely bonkers on Tuesday, surging over 600% in what might be one of the wildest rallies we have seen from a small biotech in recent memory. The shares jumped from a close of $3.71 the day before to an intraday high around $25.99, fueled by a massive pre-market buying spree.

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended June 30, 2025.

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: